Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Apr;98(4):e44-5.
doi: 10.3324/haematol.2012.082040.

Farnesyl and geranylgeranyl transferase inhibitors: an anti-inflammatory effect. Comment to "Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells" Haematologica. 2013;98(1):31-40

Giulio Kleiner, Annalisa Marcuzzi, Giuseppina Campisciano, Sergio Crovella
Comment

Farnesyl and geranylgeranyl transferase inhibitors: an anti-inflammatory effect. Comment to "Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells" Haematologica. 2013;98(1):31-40

Giulio Kleiner et al. Haematologica. 2013 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Schematic representation of mevalonate pathway. In bold characters the compounds that can be used in order to modify the pathway. Lova: lovastatin; Ald: alendronate; GOH: geraniol; ManA: manumycin A; Tip: tipifarnib; Lon: lonafarnib.
See this image and copyright information in PMC

Comment on

References

    1. Hechinger AK, Maas K, Dürr C, Leonhardt F, Prinz G, Marks R, et al. Inhibition of protein geranylgeranylation and farnesylation protects against GvHD via effects on CD4 effector T cells. Haematologica. 2013;98(1):31-40 - PMC - PubMed
    1. Zhang FL, Casey PJ. Protein prenylation: Molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-69 - PubMed
    1. Karp JE, Vener TI, Raponi M, Ritchie EK, Smith BD, Gore SD, et al. Multiinstitutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood. 2012;119(1):55-63 - PMC - PubMed
    1. Karp J, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97(11):3361-9 - PubMed
    1. Marcuzzi A, De Leo L, Decorti G, Crovella S, Tommasini A, Pontillo A. The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency. Pediatr Res. 2011;70(1):78-82 - PubMed

MeSH terms